Netilmicin is an aminoglycoside used to treat a wide variety of infections in the body. Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.
- Mechanism
- Curator reviewed
Aminoglycosides like netilmicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically netilmicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes, leaving the bacterium unable to synthesize proteins vital to its growth.
- Primary indication
- For the treatment of bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains.Curator reviewed · 14 structured indications
- Formula / weight
- C21H41N5O7 · 475.587 g/mol (avg)
- First approval
- Canada, 2022
- Also known as
- 1-N-Ethylsisomicin · Netilmycin
Resolves to
CIDUJQMULVCIBT-MQDUPKMGSA-NSMILESCCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Netilmicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account